In an ongoing quest to achieve enhanced recovery pathways among patients who undergo robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD) for treatment of muscle-invasive or high-risk noninvasive bladder cancer, Mount Sinai has developed a protocol that eliminates opioids from postoperative pain management with exceptional results.
